Dr. ihsan edan abdulkareem alsaimary
PROFESSOR IN MEDICAL MICROBIOLOGY AND MOLECULAR IMMUNOLOGY
ihsanalsaimary@gmail.com
mobile : 009647801410838
university of basrah - college of medicine - basrah -IRAQ
5. If protective immune response levels are high in the general
population, the possibility of dissemination of an infection is low.
For this reason it is so important to follow the immunisation programmes
until the infection can be considered erradicated
Measles cases / protection
6. Innate response / inflammation
Specific response
Red cells
Platelets
Specific response
7. How and where the infections enter the body
Distribution and recirculation
8. A main characteristic of the immune response is its ability to
recognise antigens in any part of the body and distribute effector
cells and antibodies throughout the organism
9. Most cells of the immune response recirculate throughout the
body and in lymph nodes they mature to produce antibodies or
cytotoxic cells that leave the lymph nodes for any part of the body
14. Specific T-cell response begins with recognition of the “intruder”
by monocyte/macrophages (through some receptors), and the
presentation of antigens (part of the proteins) to the super-specific
T-cell receptor
16. The antigen is presented to the T cells to begin complex cell activation,
induce several effector mechanisms, collaborate with B cells to produce
antibodies and secrete cytokines that mature cytotoxic cells, etc
17. HLA antigens are inherited characteristics of all human cells
(except red cells and the cornea) and their function is to recognise
the “identity” of our cells versus foreign cells or cells with
foreign antigens
Correlation between some HLA characteristics and diseases
18. The job of cytotoxic cells is to kill the cells recognised as “foreign”
(transplants) or which have foreign “particles” in the membrane
(virus-infected cells)
22. Main characteristics of the immune response:
- immunological memory (used in vaccination)
- high specificity (used in vaccination)
- recirculation (oral vaccines)
- a very high energy-consuming system
23. If there is a chronic inflammatory
response and no antibodies to
eliminate the bacteria, lesions appear
in different organs
26. Vaccines to produce antibodies to bacterial infections and toxins
e.g. Pneumococcus, tetanus toxins must stimulate the
maturation of B cells (a T-cell collaboration is needed!)
Vaccines to prevent viral infections e.g. measles, polio, HIV
must stimulate cytotoxic cells (T cells)
Most of them are very effective in healthy persons.
- HIV vaccine not achieved to date due to the extreme
variability of the virus and because it is a retrovirus
- Anti-’flu vaccines. Effective but the antigen must be
changed periodically due to changes in the virus
Vaccines against parasites (e.g. Malaria) very difficult to achieve
Not much research has been done ( affects poor countries !!!)
27. Types of vaccines :
Attenuated (“live “ vaccines) BCG, measles, chicken pox...
Inactivated most anti-bacterials, polio i.m., ‘flu...
Toxoids tetanus
Conjugated (polysaccharides and proteins) Haemophilus
Recombinant Hepatitis B
DNA vaccines under development
New vaccines :
Human Papilloma virus recombinant
Rotavirus attenuated
29. Therapeutic vaccines : to stimulate the immune response to a
specific microorganism that is infecting a patient with poor response
- Anti-tumour “vaccines”: Use of presenting cells with incorporated
tumoral antigens to induce a stronger specific response
- Immunotherapy in allergic diseases: to inhibit specific IgE synthesis
with small and repeated amounts of the allergen (tolerance)
30. PID diseases. A molecular and genetic approach.2007. 2nd ed. H.Ochs et al
31.
32.
33. GENERAL RULES :
- if an antibody response or a T-cell response cannot be produced,
vaccines will not be useful
- live or attenuated vaccines can produce the same disease in an
immunodeficient or immunocompromised individual (e.g. oral
polio)
Vaccines against bacteria are of no use in antibody deficiency
syndromes. In these cases, theoretically, vaccines against
virus COULD (?) be given , but there is no way to know
whether they are effective.
In any event, inactivated or recombinant vaccines should
ALWAYS be used !!!
36. And it is important for PID patients that national levels of
protection against the majority of microorganisms are optimum.
37. - François G et al. Vaccine safety controversies and the future
vaccination programs. Ped Infect Dis J 2005; 24(11) 953-61
- Ada, G. Vaccines and vaccination. N. Engl.J. Med 2001; 345: 1042-
1053.
- Ljungman, P., Engelhard, D., de la Camara R, et al. Vaccination of
stem cell transplant recipients: recommendations of the Infectious
Diseases working party of the EBMT. Bone Marrow Transplant 2005;
35: 737-46.
- Nachman S, Kim S, King J, et al. Safety and immunogenicity of a
heptavalent pneumococcal conjugate vaccine in infants with human
immunodeficiency virus type 1 infection. Pediatrics 2003; 112: 66-73
- Witney, CG, Farley, MM, Hadler, J. et al Decline in Invasive
Penumococcal Disease after the Introduction of Protein-Polysaccharide
Conjugate Vaccine. N.Engl.J.Med 2003; 348: 1737-46
Some references